Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Sterling Financial Planning Inc.

Sterling Financial Planning Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,653 shares of the company’s stock after selling 600 shares during the quarter. Johnson & Johnson accounts for approximately 1.3% of Sterling Financial Planning Inc.’s holdings, making the stock its 21st biggest position. Sterling Financial Planning Inc.’s holdings in Johnson & Johnson were worth $1,904,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Johnson & Johnson by 18.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after buying an additional 3,912,430 shares during the last quarter. FMR LLC lifted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC lifted its position in shares of Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of Johnson & Johnson by 52.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Johnson & Johnson by 37.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 233,611 shares of company stock worth $40,960,735. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The stock’s 50-day moving average price is $175.98 and its 200 day moving average price is $171.06.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period in the previous year, the company posted $2.13 earnings per share. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Barclays assumed coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target for the company. Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Atlantic Securities cut their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James cut their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Finally, Morgan Stanley cut their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.